While I would question some of the details of the

While I would question some of the details of the letter, I absolutely agree with the main premise. Dr. Patterson was an asset, and for whatever reason, we are no longer working with him. In the mean time, we have not finished our CD12 trial, and Bruce has written 3 more papers about COVID, including the longhauler paper. Working together would be in the best interest of the shareholders.